

Special Issue

Antibody Constructs

Message from the Guest Editors

Antibody fragments are under development as a next generation antibody therapeutic that takes advantage of their smaller sizes in comparison to a full antibody. They have unique structural characteristics, and hence challenges, which may differ from those of full antibodies in regard to production, purification/refolding, and formulation. The current Special Issue welcomes contributions from experts in the field that address and review the current state-of-the-art technology and developments in the field of antibody fragments.

Guest Editors

Dr. Satoshi Ohtake

Pharmaceutical R&D, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA

Dr. Tsutomu Arakawa

Alliance Protein Laboratories, 6042 Cornerstone Ct West, Suite A1, San Diego, CA 92121, USA

Deadline for manuscript submissions

closed (30 November 2014)



Antibodies

an Open Access Journal
by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed



mdpi.com/si/2909

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)





Antibodies

an Open Access Journal
by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed



[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)



About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry, Technical University of Munich, Emil-Erlenmeyer-Forum 5, 85354 Freising (Weihenstephan), Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)